Musely / The Hair Pill

What it is

The Hair Pill is a compounded oral prescription for female pattern hair loss, sold at $32 a month starting with a three-month supply. The page names four things in it: minoxidil, dutasteride, spironolactone, and 'added supplements'. It gives a dose for none of them.

It is worth saying clearly that hair loss in women is distressing, under-treated, and expensive to address through conventional routes. A cheap, accessible telehealth option addressing it is a genuinely useful idea, and all three of these drugs are real treatments that dermatologists prescribe. Our objection is not to the concept and not to the molecules.

The finding: dutasteride, in a product for women

Dutasteride is a 5-alpha reductase inhibitor. Its FDA labelling on this point is not open to interpretation: it is contraindicated for use in women of childbearing potential, contraindicated in pregnancy, and not indicated for use in women. It is a Category X teratogen, and the specific documented harm is abnormal development of the external genitalia in male fetuses.

Specialists do prescribe it off-label to women with female pattern hair loss. That is real and it can be appropriate. In practice it is used overwhelmingly in post-menopausal women, or in women of childbearing age with rigorously documented contraception and explicit informed consent about fetal risk. It is a decision made deliberately, for a named patient, with the risk discussed out loud.

That pharmacokinetic tail is what separates dutasteride from the other two drugs here. Spironolactone is also teratogenic, but it clears quickly; stop it and the risk window closes in days. Dutasteride's does not.

We could find no pregnancy warning on the product page. We are not asserting that the clinical intake fails to ask — we cannot see it, and it may well ask thoroughly. What we can assess is that a page selling a Category X teratogen to women does not, on its face, mention pregnancy at all.

Three drugs, one pill, no titration

Even setting the dutasteride question aside, fusing these three into a single tablet is a design decision with real clinical costs.

• ▸Spironolactone is conventionally titrated — started at 25 to 50 mg and increased toward 100 to 200 mg as tolerance allows. A fixed combination cannot be titrated without changing the dose of everything else at the same time.
• ▸Oral minoxidil can cause reflex tachycardia and fluid retention. If that happens, the correct response is to reduce or stop the minoxidil — not to stop the spironolactone that may be working well.
• ▸Spironolactone warrants baseline and periodic potassium, renal function and blood pressure checks, particularly in older women. Minoxidil warrants cardiovascular attention. Dutasteride warrants a pregnancy conversation. These are three different monitoring schedules on three different clocks.
• ▸If a woman decides she wants to conceive, she needs the dutasteride stopped months in advance. In a combination pill that means stopping her entire treatment.

On monitoring specifically, we want to be accurate rather than alarmist. The evidence on routine potassium testing in younger women is genuinely mixed — a large review of women under 45 taking spironolactone for dermatological indications found no clinically meaningful potassium elevations, and frequent monitoring in that group mostly detects results of no consequence. The risk is concentrated in older women and in those on interacting medication. That nuance is a reason to screen intelligently, not a reason to skip screening.

The 57% figure is contradicted by hair biology

Fifty-seven percent of patients reported visible improvement by day thirty, from 13,904 patients logging results at days 7, 30 and 60. The methodological objection is the familiar one — self-reported, uncontrolled, unblinded, assessed by the purchaser.

But this is the least biologically plausible claim we have assessed in this range, and it is not close. Hair grows on a cycle measured in months. Meaningful change in density or shedding is not apparent before three to six months of consistent treatment on any of these drugs.

Worse, minoxidil is known to cause an initial increase in shedding in the first weeks as follicles are pushed out of the resting phase into a new growth phase. The expected experience at day thirty is not improvement. For many people it is more hair in the shower.

The company sells a three-month initial supply, which correctly reflects that this takes time. Then it headlines a thirty-day figure that sets people up to conclude it failed during the shedding phase. Those two decisions are in direct conflict.

Who is doing the prescribing

The page describes the process as a designated solution expert reviewing photographs of your concern to create your custom solution. On other Musely product pages we have reviewed, the language is board-certified dermatologists.

'Solution expert' is not a clinical title and we do not know what it denotes here — it may well be a customer-facing term for a licensed prescriber, and a prescription cannot lawfully be issued without one. But this is the product in the range with the most consequential contraindications, and it is the one where the page is least specific about who is applying them.

If you have hair loss and were considering this

• ▸The underlying idea is sound. Female pattern hair loss is treatable and these are among the drugs that treat it. Do not let this review put you off treatment.
• ▸Ask a clinician to prescribe them individually, so each can be titrated, monitored and stopped on its own terms.
• ▸Ask specifically whether you need dutasteride at all. Many women do well on minoxidil and spironolactone alone, without the Category X drug or its five-month tail.
• ▸If you are of childbearing potential and dutasteride is proposed, have the contraception conversation explicitly and get the fetal risk explained to you directly.
• ▸Get a baseline blood pressure, and potassium and renal function if you are older or on interacting medication.
• ▸Expect increased shedding in the first two months. It is not failure; it is the mechanism.
• ▸Judge it at six months, with standardised photographs taken in the same light and position.

Where we stand

This is our second avoid verdict and it is the least equivocal one. Not because the drugs are wrong — they are the right drugs — and not because the price is wrong, because $32 a month is a genuinely good answer to a genuine access problem.

It is because a product sold exclusively to women contains a drug whose own label says it is contraindicated in women of childbearing potential and not indicated for use in women; because that drug takes four to six months to clear after a decision to stop; because no dose is published for it or for the two other systemic drugs beside it; because the supplements are unnamed; because no monitoring is described; and because we could find no mention of pregnancy on the page at all.

Any one of those would warrant caution. Together they describe a safety architecture that is not adequate to what is being dispensed. As with every other criticism in this register, most of the fix is editorial rather than pharmaceutical — publish the doses, name the supplements, state the pregnancy contraindication in the largest type on the page, describe the monitoring, and let people decline the dutasteride.